International Supply Contract
Sai Parenterals Secures AUD 202 Million OTC Medicines Supply Agreement with Australia’s Leading Pharmacy Network
NSE
saiparent
BSE
544742
Sai Parenterals Limited announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has entered into an exclusive OTC medicines supply agreement with Australia’s leading pharmacy network. The contract is valued at AUD 202 million (approximately ₹1,300 crore) with an initial tenure of 7.5 years, extendable by another 3 years through mutual consent.
PRICE-SENSITIVE TRIGGER
Event: Award of Long-Term International OTC Medicines Supply Agreement
Type: International Supply Contract
Impact: Positive
Immediate Effect: The agreement significantly strengthens Sai Parenterals’ international business by securing a long-term revenue-generating supply arrangement in the Australian pharmaceutical market.
Key Metrics:
- Contract Value: AUD 202 Million
- Equivalent Value: Approximately ₹1,300 Crore
- Exchange Rate Used: 1 AUD = ₹64.5
- Contract Type: Exclusive OTC Medicines Supply Agreement
- Initial Contract Period: 7.5 Years
- Extension Option: Additional 3 years upon mutual consent
- Effective Date: July 1, 2026
Highlight:
- Sai Parenterals has secured a ₹1,300 crore long-term international supply agreement, providing multi-year revenue visibility through its Australian subsidiary.
What Happened ?
Sai Parenterals Limited informed the stock exchanges that its subsidiary, Noumed Pharmaceuticals Pty Limited, has signed an exclusive OTC medicines supply agreement with Australia’s leading pharmacy network.
The agreement carries a contract value of AUD 202 million (approximately ₹1,300 crore) and becomes effective from July 1, 2026. The contract will remain valid for 7.5 years, with an option to extend for another 3 years based on mutual agreement between both parties.
Key Details
Contract Overview:
- Contract awarded to subsidiary Noumed Pharmaceuticals Pty Limited.
- Customer is Australia’s Leading Pharmacy Network.
- Contract value stands at AUD 202 million (approximately ₹1,300 crore).
- Nature of contract:
- Exclusive OTC medicines supply agreement.
- Effective date:
- July 1, 2026.
- Initial contract duration:
- 7.5 years.
- Extension clause:
- Additional 3-year extension upon mutual consent.
- Customer classification:
- International entity.
- Geography:
- Australia.
Note:
- The company has not disclosed product-wise volumes, annual revenue contribution, profitability expectations or shipment schedule under the agreement.
Risk Analysis
Summary:
- The long-term agreement improves international business visibility and export opportunities. However, execution performance, regulatory compliance and customer demand will determine the ultimate financial benefits.
Key Risks:
- Revenue realization depends on successful execution over the contract period.
- Regulatory approvals and pharmaceutical compliance requirements remain critical.
- Customer demand may fluctuate during the contract tenure.
- Financial contribution has not yet been quantified by the company.
Worst Case:
- Any execution delays, regulatory issues or lower-than-expected procurement by the customer could reduce the expected revenue benefits from the agreement.
Risk Level: Low
Company Commentary
- Subsidiary Noumed Pharmaceuticals Pty Limited has entered into an exclusive OTC medicines supply agreement.
- The agreement is with Australia’s leading pharmacy network.
- The contract value is AUD 202 million (approximately ₹1,300 crore).
- The agreement becomes effective from July 1, 2026.
- The initial contract period is 7.5 years, with an option to extend by 3 years upon mutual consent.
- The promoter, promoter group and group companies have no interest in the entity awarding the contract.
- The transaction does not qualify as a related-party transaction and is conducted on an arm’s length basis.
Official Exchange Filing: Sai Parenterals Limited
